CLAIM AMENDMENTS

- 1. (Withdrawn.) A method for preventing photoaging in human skin, by administering an EGF-R protein tyrosine kinase inhibitor to the human whose skin is exposed to UV radiation.
- 2. (Withdrawn.) The method of claim 1, wherein the administration is topical.
- 3. (Withdrawn.) The method of claim 1, wherein the administration is prior to exposure to UV radiation.
- 4. (Withdrawn.) The method of claim 3, wherein the administration is at least six (6) hours prior to exposure.
- 5. (Withdrawn.) The method of claim 1, wherein the tyrosine kinase inhibitor is selected from the group consisting of isoflavones, suramin sodium (and related derivatives), heribimycin-A, lavendustin-A, erbstatin, benzylidenemalononitriles, brominated quinazolines, tyrphostins, phenylaminopyridines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinopthalimides, anthraquinones, and mixutres thereof.
- 6. (Withdrawn.) The method of claim 4, further comprising administering a retinoid.
- 7. (Withdrawn.) The method of claim 5, wherein the isoflavone is genistein or quercetin.
- 8. (Currently amended.) A composition for preventing reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an <u>effective amount of an EGF-R</u> protein tyrosine kinase inhibitor admixed in a dermatologically suitable carrier therefor, wherein the EGF-R

09/891,881 Page 2 of 9 100UM-010A

TO:USPTO

inhibitor is selected from the group consisting of suramin sodium, heribimycin-A. tyrphostins, brominated quinazolines, phenylaminopyrimidines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinopthalimides, anthraquinones, PD 153035, SU-5417, SU-6668, staurosporine, aeroplysinin. layendustin A, piceatannol, hymenialdisine, and derivatives thereof, and mixtures thereof.

- 9. (Original.) The composition of claim 8, further comprising at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, antioxidants, UV sunscreens, and compatible mixtures thereof.
- 10. (Original.) The composition of claim 9, comprising a UVA blocker and a UVB blocker, and at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, and antioxidants, and compatible mixtures thereof.
- 11. (Original.) The composition of claim 10, wherein the additional compound is a retinoid.
- (Original.) The composition of claim 11, wherein the retinoid is retinol.
- 13. (Currently amended.) A composition for preventing reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an effective amount of an EGF-R protein tyrosine kinase inhibitor and an effective amount of a retinoid admixed in a dermatologically suitable carrier therefor, wherein the EGF-R inhibitor is selected from the group consisting of suramin sodium, heribimycin-A, tyrphostins, brominated quinazolines, phenylaminopyrimidines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles,

09/891,881 Page 3 of 9 100UM-010A dianilinopthalimides, anthraquinones, SU-5417, SU-6668, staurosporine, aeroplysinin, lavendustin A, piceatannol, hymenialdisine, and derivatives thereof. and mixtures thereof.

- (Original.) The composition of claim 13, wherein the retinoid is retinol or retinoic acid.
- 15. (Currently amended.) The composition of claim 13, wherein the EGF-R inhibitor [[is]] <u>further comprises</u> an isoflavone.
- 16. (Original.) The composition of claim 15, wherein the isoflavone is genistein.
- 17. (New.) A composition for reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation produced by the process comprising:
 - providing a non-isoflavone candidate compound selected from the group consisting of brominated quinazolines, phenylaminopyrimidines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinopthalimides, anthraquinones, derivatives thereof, and mixtures thereof:
 - screening said candidate compound for ability to diminish activation of EGFR to identify a successful candidate compound; and admixing a non-toxic, effective amount of said successful candidate compound with a compatible dermatological carrier.
- 18. (New.) The composition of claim 17, further comprising admixing at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, antioxidants, UV sunscreens, and compatible mixtures thereof.

09/891,881 Page 4 of 9 100UM-010A

- 19. (New.) The composition of claim 18, wherein a retinoid, a P-450 inhibitor, and an antioxidant are admixed.
- (New.) The composition of claim 18, wherein the antioxidant is 20. selected from the group consisting of genistein, genistin, quercetin, glutathione, N-acetyl cystein, green tea extract, carotenoids, tocopherols, ascorbic acid, lipoic acid, Erbstatin, and mixtures thereof.